Nuvation Bio (NUVB) to Release Quarterly Earnings on Thursday

Nuvation Bio (NYSE:NUVB - Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Nuvation Bio Trading Down 0.8 %

Shares of NYSE NUVB traded down $0.02 during midday trading on Friday, reaching $1.96. The company's stock had a trading volume of 2,464,587 shares, compared to its average volume of 2,319,323. The stock has a 50 day simple moving average of $2.50 and a 200-day simple moving average of $2.62. The stock has a market capitalization of $657.99 million, a price-to-earnings ratio of -0.90 and a beta of 1.45. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16.

Wall Street Analyst Weigh In

Several brokerages have commented on NUVB. HC Wainwright boosted their price target on shares of Nuvation Bio from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Wedbush reiterated an "outperform" rating and set a $5.00 target price on shares of Nuvation Bio in a report on Monday, January 6th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $8.20.

Remove Ads

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.